Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies (vol 10, e003024, 2022)

被引:0
|
作者
Michielin, O.
Lalani, A.
Robert, C.
机构
关键词
D O I
10.1136/jitc-2021-003024corr1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页数:1
相关论文
共 43 条
  • [41] "Whole-Genome Sequencing-Based Re-Identification of Pseudomonas putida/fluorescens Clinical Isolates Identified by Biochemical Bacterial Identification Systems" (vol 10, e02491-21, 2022)
    Tohya, Mari
    Teramoto, Kanae
    Watanabe, Shin
    Hishinuma, Tomomi
    Shimojima, Masahito
    Ogawa, Miho
    Tada, Tatsuya
    Tabe, Yoko
    Kirikae, Teruo
    MICROBIOLOGY SPECTRUM, 2023, 11 (02)
  • [43] Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany (vol 54, pg 88, 2020)
    Schneeweiss, Andreas
    Ettl, Johannes
    Lueftner, Diana
    Beckmann, Matthias W.
    Belleville, Erik
    Fasching, Peter A.
    Fehm, Tanja N.
    Geberth, Matthias
    Haeberle, Lothar
    Hadji, Peyman
    Hartkopf, Andreas D.
    Hielscher, Carsten
    Huober, Jens
    Ruckhaeberle, Eugen
    Janni, Wolfgang
    Kolberg, Hans Christian
    Kurbacher, Christian M.
    Klein, Evelyn
    Lux, Michael P.
    Mueller, Volkmar
    Nabieva, Naiba
    Overkamp, Friedrich
    Tesch, Hans
    Laakmann, Elena
    Taran, Florin-Andrei
    Seitz, Julia
    Thomssen, Christoph
    Untch, Michael
    Wimberger, Pauline
    Wuerstlein, Rachel
    Volz, Bernhard
    Wallwiener, Diethelm
    Wallwiener, Markus
    Brucker, Sara Y.
    BREAST, 2021, 55 : 138 - 139